pivekimab sunirine-pvzy

FDA Drug Profile — DECNUPAZ

pivekimab sunirine-pvzy is listed in the FDA National Drug Code directory with 1 NDC code, marketed under brand name including DECNUPAZ. Available dosage form: injection, powder, lyophilized, for solution.

Drug Details

Generic Name
pivekimab sunirine-pvzy
Brand Names
DECNUPAZ
Application Number
BLA761460
Sponsor
AbbVie Inc.
NDC Codes
1
Dosage Forms
INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
Routes
INTRAVENOUS
Active Ingredients
PIVEKIMAB SUNIRINE

Indications and Usage

1. INDICATIONS AND USAGE DECNUPAZ is indicated for the treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). DECNUPAZ is a CD123-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). ( 1 )